Sanofi (NYSE:SNY) is reportedly considering a bid for Actelion Pharmaceuticals (VTX:ATLN), competing with an offer made to the Swiss biotech by Johnson & Johnson (NYSE:JNJ). Bloomberg reported that Sanofi is working with advisers to assess its options and has made its interest known informally to Actelion. The French drugmaker has not made a formal comment on the matter and has not decided if it will move forward with a bid.
J&J has been in talks with Actelion about what reports have said may be a $27 billion takeover bid. The high premium offer is tempting to shareholders, who would rather take the cash now than bet on Actelion CEO Jean-Paul Clozel’s risky pipeline for therapeutics targeting rare diseases.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi throws hat in the ring with J&J’s in Actelion pursuit appeared first on MassDevice.